BNT327, a PD-L1/VEGF therapy, is still currently being manufactured in China, but BioNTech is working to establish a ...

Vanotech is the sponsor representative and is responsible for the clinical development programme for the therapy in the US.

Innovent Biologics recently announced its latest 1-year results from its phase 2 clinical trial of efdamrofusp alfa, a ...

a VEGF receptor 2 antagonist; and Retsevmo, a selective and potent RET kinase inhibitor. The company is also developing IBI-326, a fully-human BCMA CAR T-cell therapy; IBI-376, an oral inhibitor ...

Discover "Bevacizumab - Biosimilar Insight, 2025," which analyzes 25+ companies and 30+ drugs in the bevacizumab biosimilars landscape. The report covers marketed drugs, pipeline molecules, and ...

According to DevelInsight analysis, the estimated total diagnosed prevalent cases of Idiopathic Pulmonary Fibrosis in the 7MM were approximately 193,000 in 2023; this number is expected to increase in ...

Dosing our first patient in the VAN-2401 phase 1 trial is an important milestone in the advancement of KH658 by exploring the ...

In addition to the presentations, Viral Kansara, PhD, Vice President, Preclinical Development moderated an ARVO session entitled “Retina/RPE: New drugs, mechanisms of action, and toxicity” and Dr.

IBI302), a recombinant human vascular endothelial growth factor receptor (VEGFR)-antibody human complement receptor 1 (CR1) ...

Subcutaneous administration generally safe and well-tolerated across multiple doses>80% reduction in anti-VEGF intravitreal injection burden in wet AMD and DME study eyes and >75% total reduction in ...